Management
- Outside Perspective
-
As the biopharmaceutical industry undergoes massive, transformational change, many companies are looking outside the industry to fill leadership positions.
- Simulating Science
-
Through clinical trial simulation, researchers can generate a fuller understanding of their drug and its potential effects, leading to better designed—and possibly less expensive—trials.
- Which Way Forward?
-
Amidst the constant need to secure steady financing, emerging biotech companies are considering options that will not only produce a larger return, but also increase the likelihood of getting a product to market.
- The New Face of Outsourcing
-
The pressing need to control costs and reduce development timelines has led many biopharmaceutical manufacturers to increasingly outsource components of their clinical research programs.
- Rethinking Informed Consent
-
Cultural understanding, technology and pragmatism are helping create new approaches to clinical research subject enrollment.
- Change is Constant
-
To fully optimize adaptive clinical trial design, the proper technological tools must be in place.
- The Calm Before the Storm
-
A number of fundamental factors could lead to a new and accelerated wave of consolidation in the pharmaceutical and biotech industries.
- Blending with Biotech
-
The strength of the U.K. biotech sector makes it inviting to large pharmaceutical companies looking to expand product portfolios.
- Continuing Ed
-
In the United States, clinical education programs can improve patient compliance and lead to better patient care.
- Pulling the Plug
-
Retiring a failed product is never an easy process, particularly when the withdrawal is for safety reasons. Adhering to a risk management process can help companies keep the damage under control.
Web Exclusives
- Statistical Advantage
-
Gary Shorter, director of biostatistics for Quintiles, talks to Envisage editor Adam Istas about the growing importance of incorporating biostatistical analysis into all stages of drug development.
- Measure for Measure
-
A proposed Health Care Comparative Effectiveness Research Institute in the United States may force the biopharmaceutical industry to emphasize patient outcomes and quality of life issues when developing a new medicinal product.